

华北理工大学医学伦理委员会审批报告
*Approval Letter of Ethics Committee of North China University of
Science and Technology*

审批号_2022032_

审批日期: 2022 年 3 月 1 日

Approval No.

Issued Date

研究题目: 靶向阻断 Piezo1/NCLX 钙摄取和钠-钙置换信号限制线粒体钙循环抑制胃癌细胞腹腔转移

Study Title: Targeted blocking of Piezo1 / NCLX calcium uptake and sodium calcium replacement signals, limiting mitochondrial calcium circulation and inhibiting peritoneal metastasis of gastric cancer cells

试验方案版本号与日期 Protocol No. & Version date: NA

知情同意书版本号及日期 Informed Consent Form version and date: NA

研究药物名称(中、英文)(Chinese/English): NA

临床试验批文单位及批文号: Clinical trial approval No. and issued by: NA

研究单位及主要负责人: 华北理工大学附属医院/王潇飞

Study site and principal investigator: Affiliated Hospital of North China University of Science and Technology/Xiaofei Wang

申办单位名称: Sponsor Name: 华北理工大学附属医院

审批意见 Evaluation Comments:

伦理委员会于 20_22_年_3_月_1_日对上述研究方案及有关内容进行了认真的讨论并进行了投票表决, 投票人数_17_人。同意:_17_票, 反对:_0_票, 修订后再审_0_票。

伦理委员会决议: 同意 该项目开展研究。(填写: 同意、反对或暂停)

此批文有效期自签字之日起 3 年。

The Ethics Committee (IRB) discussed the protocol titled and dated above and the relevant documents on Mar. 1st, 2022. Total _17_ members voted. The Ethics Committee has approved (approved, against or suspended) the initiation of the study.

The period of validity is 3 year since the signature of EC.

伦理委员会主任委员签名: _____

Signature of Chairman of the Ethics Committee

抄送: 1. 临床研究人员签收 _____

Signature of investigator

2. 申办单位 Sponsor

日期: _____

Date

日期: _____

Date



地址: 河北省唐山市曹妃甸新城渤海大道 21 号邮编: 063210 电话: 0315-8805225